• Article

Specialist integrated haematological malignancy diagnostic services

Citation

Dalley, C., Basarir, H., Wright, J. G., Fernando, M., Pearson, D., Ward, S. E., ... Snowden, J. A. (2015). Specialist integrated haematological malignancy diagnostic services: An activity based cost (ABC) analysis of a networked laboratory service model. Journal of Clinical Pathology, 68(4), 292-300. DOI: 10.1136/jclinpath-2014-202624

Abstract

Aims Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS) were introduced as a standard of care within the UK National Health Service to reduce diagnostic error and improve clinical outcomes. Two broad models of service delivery have become established: 'co-located' services operating from a single-site and 'networked' services, with geographically separated laboratories linked by common management and information systems. Detailed systematic cost analysis has never been published on any established SIHMDS model.

Methods We used Activity Based Costing (ABC) to construct a cost model for our regional 'networked' SIHMDS covering a two-million population based on activity in 2011.

Results Overall estimated annual running costs were 1 pound 056 260 per annum (733 pound 400 excluding consultant costs), with individual running costs for diagnosis, staging, disease monitoring and end of treatment assessment components of 723 pound 138, 55 pound 302, 184 pound 152 and 94 pound 134 per annum, respectively. The cost distribution by department was 28.5% for haematology, 29.5% for histopathology and 42% for genetics laboratories. Costs of the diagnostic pathways varied considerably; pathways for myelodysplastic syndromes and lymphoma were the most expensive and the pathways for essential thrombocythaemia and polycythaemia vera being the least.

Conclusions ABC analysis enables estimation of running costs of a SIHMDS model comprised of 'networked' laboratories. Similar cost analyses for other SIHMDS models covering varying populations are warranted to optimise quality and cost-effectiveness in delivery of modern haemato-oncology diagnostic services in the UK as well as internationally.